Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT03465540 Terminated - Multiple Myeloma Clinical Trials

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Start date: August 17, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.

NCT ID: NCT03455504 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

V-FIRST
Start date: October 26, 2018
Phase: Phase 2
Study type: Interventional

This study will test the effectiveness and safety of Venetoclax in combination with standard induction regimen for patients with acute leukemia and poor prognosis.

NCT ID: NCT03454984 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Start date: November 2018
Phase: Phase 2
Study type: Interventional

High risk MDS (Myelodysplastic Syndrome) patients will be treated with SGI-110 after Allogeneic Stem Cell Transplantation in the hypothesis that SGI-110 maintenance given early after HSCT can prevent relapse without increasing non-relapse mortality translating in an improved disease-free survival.

NCT ID: NCT03451084 Completed - Clinical trials for Acute Myeloid Leukemia

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Start date: January 5, 2018
Phase: Phase 2
Study type: Interventional

ASLAN003-003 is a multi-center, Phase IIA study to evalute the efficacy of ASLAN003 in AML patients who are ineligible for standard treatment with an expansion cohort in relapsed/refractory patients, and to determine the appropriate dose of ASLAN003 in combination with azacitidine in older (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options.

NCT ID: NCT03450512 Recruiting - Clinical trials for Acute Myeloid Leukemia

Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy

DECLAM
Start date: January 14, 2019
Phase:
Study type: Observational

Neutropenia after induction or consolidation therapy for acute myeloid leukemia (AML) patients is associated with a high morbi-mortality rates, especially due to infectious complications. These are managed according to international recommandations (ECIL and IDSA) with antibiotherapy and antifungal strategy. Although the patients suffer of digestive symptoms, intestinale complications are really less explored. Neutropenic enterocolitis (NE), cytomegalovirus (CMV) colitis, Clostridium difficile colitis, specific lesion, ischemic colitis are not well-known. No prospective study evaluate NE and these digestive complications which have high morbi-mortality rates.

NCT ID: NCT03449745 Completed - Clinical trials for Acute Myeloid Leukemia

Immune Checkpoint Receptors in AML-Leukemic Initiating Cells

ICAML-LIC
Start date: May 29, 2018
Phase:
Study type: Observational

This project aim at deciphering immune mechanisms that allow the immunoescape of AML initiating cells.

NCT ID: NCT03442452 Completed - Clinical trials for Acute Myeloid Leukemia

AML Electronic Decision Aid

Start date: February 7, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.

NCT ID: NCT03441048 Completed - Clinical trials for Acute Myeloid Leukemia

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Start date: May 22, 2018
Phase: Phase 1
Study type: Interventional

This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose, recommended phase 2 dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design with a five-patient cohort at the recommended phase 2 dose.

NCT ID: NCT03439371 Recruiting - Clinical trials for Acute Myeloid Leukemia

Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia

MTSA
Start date: January 8, 2019
Phase: N/A
Study type: Interventional

This study aims at evaluating the safety and the tolerance of the micro-transplantation in elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic transplantation.

NCT ID: NCT03435848 Completed - Clinical trials for Acute Myeloid Leukemia

Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy

ELPIS
Start date: August 14, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assesses the benefit, safety, and pharmacokinetics (PK) of BST-236 in patients with newly-diagnosed Acute Myeloid Leukemia (AML) who are not eligible for standard induction chemotherapy due to advanced age or comorbidities. The Complete Remission (CR) rate following treatment with BST-236 will be compared to the CR rate reported in historical data in a similar population.